Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

Ying Jin; Hua Bao; Xiuning Le; Xiaojun Fan; Ming Tang; Xun Shi; Jun Zhao; Junrong Yan; Yang Xu; Kelly Quek; Yasir Y Elamin; Jianhua Zhang; P Andrew Futreal; Ignacio I Wistuba; John V Heymach; Guangyuan Lou; Lan Shao; Qiong He; Chen Lin; Xue Wu; Yang W Shao; Xiaonan Wang; Jiachen He; Yamei Chen; Justin Stebbing; Ming Chen; Jianjun Zhang; Xinmin Yu

doi:10.1038/s41388-019-1143-5

Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

Oncogene. 2020 Feb;39(9):2027. doi: 10.1038/s41388-019-1143-5.

Authors

Ying Jin^{1

2

3}, Hua Bao⁴, Xiuning Le⁵, Xiaojun Fan⁴, Ming Tang⁵, Xun Shi^{1

2}, Jun Zhao^{1

2}, Junrong Yan⁶, Yang Xu⁴, Kelly Quek⁵, Yasir Y Elamin⁵, Jianhua Zhang⁷, P Andrew Futreal⁷, Ignacio I Wistuba⁸, John V Heymach⁵, Guangyuan Lou^{1

2}, Lan Shao^{1

2}, Qiong He^{1

2}, Chen Lin^{1

2}, Xue Wu⁴, Yang W Shao⁶, Xiaonan Wang⁶, Jiachen He⁶, Yamei Chen^{1

3}, Justin Stebbing⁹, Ming Chen^{10

11}, Jianjun Zhang^{12

13}, Xinmin Yu^{14

15}

Affiliations

¹ Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
² Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences & Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
³ Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, Zhejiang, China.
⁴ Translational Medicine Research Centre, Geneseeq Technology Inc., Toronto, ON, Canada.
⁵ Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁶ Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
⁷ Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁸ Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁹ Department of Surgery and Cancer, Division of Cancer, Imperial College London, Imperial Centre for Translational and Experimental Medicine (ICTEM), London, W12 0NN, UK.
¹⁰ Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China. [email protected].
¹¹ Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, Zhejiang, China. [email protected].
¹² Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. [email protected].
¹³ Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. [email protected].
¹⁴ Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China. [email protected].
¹⁵ Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences & Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. [email protected].

PMID: 31831835
DOI: 10.1038/s41388-019-1143-5

Abstract

The original version of this Article omitted the following from the Acknowledgements: Professor Stebbing sits on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. This has now been corrected in both the PDF and HTML versions of the Article.

Publication types

Published Erratum

Grants and funding

NIHR-RP-011-053/DH_/Department of Health/United Kingdom